SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Sunday, April 28, 2013

The patent litigation bug bites Indian pharma companies: Symed sues Glenmark

Posted on 2:02 PM by Unknown
Image from here
In a sign of yet more litigation between Indian pharmaceutical companies, the Hyderabad based Symed Labs Ltd., represented by Fidus Law Chambers has sued the Mumbai based Glenmark Pharmaceuticals Laboratories before the Delhi High Court for allegedly infringing two of its patents: 213062 & 213063. The ‘062 patent was granted for “Novel intermediates for linezolid and related compounds” while the ‘063 patent was granted for “A novel process for the preparation of linezolid and related compounds”. 

Incidentally, both these patents were also the subject of two different patent infringement lawsuits filed by Symed against Optimus Pharma Pvt. Ltd on July 3, 2012 and against Sharon Bio-Medicine on July, 13, 2012. The Delhi High Court had granted interim injunctions in both cases restraining Optimus Pharma Pvt. Ltd. and Sharon Medicine from infringing the patents in question. Rajiv had written a detailed post on the Optimus lawsuit over here and I recommend reading it. 

In the present case, Glenmark had already filed caveats before the Delhi High Court in anticipation of the lawsuit and was thus present before the Court on the first day of hearing, pre-empting any interim injunction orders. Justice Rajiv Sahai Endlaw, declined to grant an ex-parte interim injunction and has posted the matter for further hearing on May 29th, 2012 after Glenmark has filed its replies to Symed’s application. 

From a reading of the order available over here, Symed has claimed to have found certain compounds in Glenmark’s product which indicate that it has used Symed’s patented process. Glenmark for its part has accused Symed of not informing the court that it was aware of Glenmark manufacturing linezolid since 2005 and that Glenmark was also purchasing the linezolid from Symed as late as 18th April, 2012. 

In this backdrop, it is interesting to note, that both Symed and Glenmark have been magnets for patent litigation in the recent past. Apart from the suit filed by Symed against Optimus and Sharon Biosciences in 2012, Symed was itself sued, in 2011, for patent infringement by Vifor International, a European company, for infringement of patent no. 221536, which was granted for “Water soluble iron carbohydrate complex and a process for producing water soluble iron carbohydrate complex”. At the time Symed had been at the receiving end of an ex-parte interim injunction from the Delhi High Court and we had blogged about the same over here. As for Glenmark, it has been at the receiving end of a patent infringement lawsuit filed by Merck for the infringement of its patents covering Januvia. Madhulika had written a post covering the case against Glenmark over here. 

Apart from these lawsuits, there was also the patent litigation between two other Indian pharmaceutical companies, Issar Pharmaceuticals and Ind-Swift, which we had blogged about over here. The increasing patent litigation between Indian pharmaceutical companies, is a sign of increasing competition between pharmaceutical companies and surprisingly it is the smaller companies which are more aggressive in suing for patent infringement. 

All in all, it’s a good time to be a patent lawyer in India.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Glenmark, Indian patent litigation, Indian Pharma | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Guest Post: A Step Forward and a Step Back for the Print Disabled
    We are happy to bring our readers our first guest post entry from our SpicyIP Fellowship applicants. Snigdha Roy, a 3rd year student from G...
  • Open Access: What is it about?
    Aaron Swartz' s recent suicide has sparked discussion all over the internet, with much of it to do with his  strong belief in the moral ...
  • Delhi University Restrained for Alleged Admission of Infringement: True Lies?
    This afternoon, in response to my post announcing a petition relating to the OUP-Delhi University copyright dispute, we were informed that...
  • SPICY IP TIDBIT: IPAB reverts “DARJEELING LOUNGE” matter to Registrar
    Background ITC Limited, the appellant, applied for the mark “DARJEELING LOUNGE” which was advertised on 07.02.2005.  Notice of opposition ...
  • Del HC hits a sixer: The Boundaries of Copyright and Cricket
    Our friends at Medianama have pointed us in the direction of one of the most superbly analysed IP judgments that I have read in a long time...
  • SpicyIP Tidbit: An IP Thriller from an IP lawyer
    In an exciting first for the community of intellectual property lawyers in India, Dr. Kalyan Kankanala has penned a thriller novel based, w...
  • Royal Orchid Hotels scores a crucial trademark victory in its long running battle with the Kamat Group
    In a decision dated 18th June, 2013 a bench of the Intellectual Property Appellate Board (IPAB), has allowed the appeals filed by Royal Orch...
  • Guest Post: The New India Guidelines on Similar Biologics
    The Government of India has recently announced certain guidelines regulating the approval of 'similar biologics' also known as bio-s...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ▼  April (51)
      • Spicy IP Weekly Review: 4th Week of April, 2013
      • Guest Post: A look at the new notice and takedown ...
      • The patent litigation bug bites Indian pharma comp...
      • DU Copyright Controversy continues: Media joins th...
      • SPICY IP TIDBIT: IPAB reverts “DARJEELING LOUNGE” ...
      • SpicyIP Tidbit: SC stays release of Zanjeer 2.0
      • Hindu-Microsoft spar over AICTE story
      • The Kit Kat Trademark Dispute
      • Oops! IPO did it again: IPAB pulls up patent offic...
      • Guest Post: T-Series’ Constitutional Challenge to ...
      • SpicyIP Tidbit: Controller General restores name o...
      • SpicyIP Tidbit: Update on the Indo-EU FTA negotiat...
      • UK Supreme Court relieves internet users of the th...
      • Guest Post: Are Genes Eligible for Patents in the ...
      • Academics "Speak" Out in Coursepack Copyright Case
      • SPICY IP TIDBIT: Tea Board refused interim injunct...
      • Scoping the constitutional challenges against the ...
      • Guest Post: US Supreme Court hears oral arguments ...
      • IPAB complains, yet again, about lack of resources...
      • Publishers Support Fair Use. Really?
      • The Competition Commission tightens the 'noose' ar...
      • Does the Madras High Court judgment on S. 126 allo...
      • Call for Papers: NLSIU announces Consilience 2013 ...
      • 'Hamara Bajaj'- infringement of trademark of Bajaj...
      • Nautanki Saala: interim relief rejected by the Bom...
      • Delhi High Court scheduled to hear 3 petitions cha...
      • Victory has a thousand fathers – CPI(M) stakes cla...
      • Delhi HC on trademark protection for domain name
      • Madras High Court strikes down amendment to S.126 ...
      • Zanjeer Battle Continues: Scriptwriters Javed Akht...
      • CPI(M): Government negotiating adverse FTA terms
      • India Joins the International Trademark System
      • Thalappakatti biryani trademark row
      • SpicyIP Weekly Review (April- Week 1)
      • FICCI announces online certificate course on IPR a...
      • Investors protest Rise in Royalty Rates paid by As...
      • The salt form jinx:Delhi HC denies interim relief ...
      • Court Stays the Screeening of Ketan Mehta's Film
      • Deconstructing the judgment of the Supreme Court i...
      • Ramesh Sippy faces setback: Bombay High Court allo...
      • Bombay High Court paves the way for the release of...
      • Bombay HC rules on Zanjeer Controversy
      • FICCI announces online certificate course on intel...
      • SpicyIP Weekly Review(March- Week 5)
      • Spicy IP tidbit:Merck files patent infringement su...
      • Patent war intensifies: Glenmark launches generic ...
      • Clarification: Trademark Infringement Suit against...
      • EU gaining a double benefit: Free Trade and GI pro...
      • Supreme Court rejects bid by Novartis to patent Gl...
      • Increased copyright prices of vintage Bollywood so...
      • Officer's Choice v. Original Choice: IPAB allows C...
    • ►  March (66)
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.